ArticleBMC cancer2018
Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.Breast cancer research : BCR · 2023Pooled it
- Body mass index increases the lymph node metastasis risk of breast cancer: a dose-response meta-analysis with 52904 subjects from 20 cohort studies.BMC cancer · 2020Pooled it
- Educational, Racial, and Geographic Inequalities in Breast Cancer Screening and Diagnosis among Brazilian Women.Journal of racial and ethnic health disparities · 2026Article
- Histological types of invasive breast cancer in 830,000 women diagnosed in England during 1988-2016.The journal of pathology. Clinical research · 2025Article
- Five-year overall and specific survival of breast cancer in great Cuiaba (MT), Brazil.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2025Article
- Article
- Survival differences between the USA and an urban population from China for all cancer types and 20 individual cancers: a population-based study.The Lancet regional health. Western Pacific · 2023Article
- Survival of Breast Cancer by Stage, Grade and Molecular Groups in Mallorca, Spain.Journal of clinical medicine · 2022Article
- Web-Based Personalized Intervention to Improve Quality of Life and Self-Efficacy of Long-Term Breast Cancer Survivors: Study Protocol for a Randomized Controlled Trial.International journal of environmental research and public health · 2022Article
- Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred.Scientific reports · 2022Article
- Type 2 Diabetes and all-cause mortality among Spanish women with breast cancer.Cancer causes & control : CCC · 2022Article
- Use of health services among long-term breast cancer survivors in Spain: longitudinal study based on real-world data.Journal of cancer survivorship : research and practice · 2022Article
- Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer.Experimental and therapeutic medicine · 2021Article
- Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Article
- Article
- The incidence of breast cancer in Canada 1971-2015: trends in screening-eligible and young-onset age groups.Canadian journal of public health = Revue canadienne de sante publique · 2020Article
- Article
- Does Breast Cancer Increasingly Affect Younger Women?International journal of environmental research and public health · 2020Article
- PBX1 is a valuable prognostic biomarker for patients with breast cancer.Experimental and therapeutic medicine · 2020Article
- A Longitudinal Study of a Multicomponent Exercise Intervention with Remote Guidance among Breast Cancer Patients.International journal of environmental research and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe incidence of breast cancer has increased since the 1970s. Despite favorable trends in prognosis, the role of changes in clinical practice and the introduction of screening remain controversial. We examined breast cancer trends to shed light on their determinants.
methodsData were obtained for 8502 new cases of breast cancer in women between 1985 and 2012 from a population-based cancer registry in Granada (southern Spain), and for 2470 breast cancer deaths registered by the Andalusian Institute of Statistics. Joinpoint regression analyses of incidence and mortality rates were obtained. Observed and net survival rates were calculated for 1, 3 and 5 years. The results are reported here for overall survival and survival stratified by age group and tumor stage.
resultsOverall, age-adjusted (European Standard Population) incidence rates increased from 48.0 cases × 100,000 women in 1985-1989 to 83.4 in 2008-2012, with an annual percentage change (APC) of 2.5% (95%CI, 2.1-2.9) for 1985-2012. The greatest increase was in women younger than 40 years (APC 3.5, 95%CI, 2.4-4.8). For 2000-2012 the incidence trend increased only for stage I tumors (APC 3.8, 95%CI, 1.9-5.8). Overall age-adjusted breast cancer mortality decreased (APC - 1, 95%CI, - 1.4 - - 0.5), as did mortality in the 50-69 year age group (APC - 1.3, 95%CI, - 2.2 - - 0.4). Age-standardized net survival increased from 67.5% at 5 years in 1985-1989 to 83.7% in 2010-2012. All age groups younger than 70 years showed a similar evolution. Five-year net survival rates were 96.6% for patients with tumors diagnosed in stage I, 88.2% for stage II, 62.5% for stage III and 23.3% for stage IV.
conclusionsBreast cancer incidence is increasing - a reflection of the evolution of risk factors and increasing diagnostic pressure. After screening was introduced, the incidence of stage I tumors increased, with no decrease in the incidence of more advanced stages. Reductions were seen for overall mortality and mortality in the 50-69 year age group, but no changes were found after screening implementation. Survival trends have evolved favorably except for the 70-84 year age group and for metastatic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.